JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC
JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC
Active, not recruiting · NCT06838338 · Registry updated 2026-01-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Active, not recruiting | Phase 1 | 2026-01-08 | NCT06838338 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Jian Li | 2 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Cancer Hospital | Beijing | China | 85 |
| Fudan University Shanghai Cancer Center | Shanghai | China | 128 |
| Peking University Cancer Hospital (Inner Mongolia Campus)/Afffliated Cancer Hospital of Inner Mongolia Medical University | Hohhot | China | 1 |
| Peking University First Hospital | Beijing | China | 72 |